Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab

Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab

Background: Few data are available about real-life cardiotoxicity associated with s.c. versus i.v. trastuzumab treatment of early-stage, HER2-positive breast cancer, and little is known about its predisposing factors. Patients and methods: We retrospectively reviewed data of 363 adult patients treat...

Full description

Bibliographic Details
Main Authors: Rita De Sanctis, Laura Giordano, Federica D’Antonio, Elisa Agostinetto, Arianna Marinello, Daniela Guiducci, Giovanna Masci, Agnese Losurdo, Monica Zuradelli, Rosalba Torrisi, Armando Santoro
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Breast
Subjects:
Trastuzumab
HER2-positive
Early breast cancer
Subcutaneous
Intravenous
Cardiac toxicity
Online Access:http://www.sciencedirect.com/science/article/pii/S096097762100343X

Internet

http://www.sciencedirect.com/science/article/pii/S096097762100343X

Similar Items